PABPN1 gene therapy for oculopharyngeal muscular dystrophy
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Oculopharyngeal muscular dystrophy (OPMD) is an autosomal dominant, late-onset muscle disorder characterized by ptosis, swallowing difficulties, proximal limb weakness and nuclear aggregates in skeletal muscles. OPMD is caused by a trinucleotide repeat expansion in the PABPN1 gene that results in an N-terminal expanded polyalanine tract in polyA-binding protein nuclear 1 (PABPN1). Here we show that the treatment of a mouse model of OPMD with an adeno-associated virus-based gene therapy combining complete knockdown of endogenous PABPN1 and its replacement by a wild-type PABPN1 substantially reduces the amount of insoluble aggregates, decreases muscle fibrosis, reverts muscle strength to the level of healthy muscles and normalizes the muscle transcriptome. The efficacy of the combined treatment is further confirmed in cells derived from OPMD patients. These results pave the way towards a gene replacement approach for OPMD treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, in studies exploring genetic strategies to treat OPMD, expression of exogenous non-expanded PABPN1 alone was not sufficient to reverse all signs of muscle dysfunction unless it was coupled with shRNA knockdown of expanded PABPN1 [22].”
In the citing paper
“These studies suggest that loss of PABPN1 function alone is not sufficient to drive OPMD related pathology.”
In the citing paper
“For several phenotypes tested, including muscle fibrosis, myofiber cross-sectional area, and cell death, vector-encoded Ala10 PABPN1 was sufficient to reverse the phenotypes caused by alanine-expanded PABPN1.”
In the citing paper
“However, some functional and molecular phenotypes were not resolved by adding back Ala10 PABPN1 alone but instead required simultaneous knockdown of expanded PABPN1.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145
Analysis of AAV Serotypes 1–9 Mediated Gene Expression and Tropism in Mice After Systemic Injection
Zincarelli, C., Soltys, S., Rengo, G., & Rabinowitz, J. E. (2008) · Molecular Therapy · doi:10.1038/mt.2008.76 · Cited by 1,490
Long-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B
Nathwani, A. C., Reiss, U. M., Tuddenham, E. G. D., Rosales, C., Chowdary, P., McIntosh, J., Della Peruta, M., Lheriteau, E., Patel, N., Raj, D., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407309 · Cited by 1,273
Immune responses to AAV vectors: overcoming barriers to successful gene therapy
Mingozzi, F., & High, K. A. (2013) · Blood · doi:10.1182/blood-2013-01-306647 · Cited by 955
MacLaren, R. E., Groppe, M., Barnard, A. R., Cottriall, C. L., Tolmachova, T., Seymour, L., Clark, K. R., During, M. J., Cremers, F. P. M., Black, G. C. M., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62117-0 · Cited by 796
Self-complementary AAV vectors; advances and applications
McCarty, D. M. (2008) · Molecular Therapy · doi:10.1038/mt.2008.171 · Cited by 515
AAV2 Gene Therapy Readministration in Three Adults with Congenital Blindness
Bennett, J., Ashtari, M., Wellman, J., Marshall, K. A., Cyckowski, L. L., Chung, D. C., McCague, S., Pierce, E. A., Chen, Y., Bennicelli, J. L., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3002865 · Cited by 395
Tardieu, M., Zérah, M., Husson, B., de Bournonville, S., Deiva, K., Adamsbaum, C., Vincent, F., Hocquemiller, M., Broissand, C., Furlan, V., et al. (2014) · Human Gene Therapy · doi:10.1089/hum.2013.238 · Cited by 261
Davies, J. E., Sarkar, S., & Rubinsztein, D. C. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddi422 · Cited by 207
Lemay, J.-F., D'Amours, A., Lemieux, C., Lackner, D. H., St-Sauveur, V. G., Bähler, J., & Bachand, F. (2010) · Molecular Cell · doi:10.1016/j.molcel.2009.12.019 · Cited by 112
Research works printed but not linked: 59
- Bouchard, J. P., Brais, B., Brunet, D., Gould, P. V. & Rouleau, G. A. Recent studies on oculopharyngeal muscular dystrophy in Quebec. Neuromuscul. Disord. 7, (Suppl 1): S22–S29 (1997). · doi:10.1016/s0960-8966(97)00077-1
- Brais, B. et al. Short GCG expansions in the PABP2 gene cause oculopharyngeal muscular dystrophy. Nat. Genet. 18, 164–167 (1998). · DOI · Paper page
- Banerjee, A., Apponi, L. H., Pavlath, G. K. & Corbett, A. H. PABPN1: molecular function and muscle disease. FEBS J. 280, 4230–4250 (2013). · DOI · Paper page
- Apponi, L. H. et al. Loss of nuclear poly(A)-binding protein 1 causes defects in myogenesis and mRNA biogenesis. Hum. Mol. Genet. 19, 1058–1065 (2009). · DOI · Paper page
- Benoit, B. et al. An essential cytoplasmic function for the nuclear poly(A) binding protein, PABP2, in poly(A) tail length control and early development in Drosophila. Dev. Cell 9, 511–522 (2005). · DOI
- de Klerk, E. et al. Poly(A) binding protein nuclear 1 levels affect alternative polyadenylation. Nucleic Acids Res. 40, 9089–9101 (2012). · DOI · Paper page
- Jenal, M. et al. The poly(a)-binding protein nuclear 1 suppresses alternative cleavage and polyadenylation sites. Cell 149, 538–553 (2012). · DOI · Paper page
- Beaulieu, Y. B., Kleinman, C. L., Landry-Voyer, A. M., Majewski, J. & Bachand, F. Polyadenylation-dependent control of long noncoding RNA expression by the poly(A)-binding protein nuclear 1. PLoS Genet. 8, e1003078 (2012). · DOI · Paper page
- Bresson, S. M. & Conrad, N. K. The human nuclear poly(a)-binding protein promotes RNA hyperadenylation and decay. PLoS Genet. 9, e1003893 (2013). · DOI · Paper page
- Bergeron, D., Pal, G., Beaulieu, Y. B., Chabot, B. & Bachand, F. Regulated intron retention and nuclear pre-mRNA decay contribute to PABPN1 autoregulation. Mol. Cell Biol. 35, 2503–2517 (2015). · DOI
- Muniz, L., Davidson, L. & West, S. Poly(A) polymerase and the nuclear Poly(A) binding protein, PABPN1, coordinate the splicing and degradation of a subset of human pre-mRNAs. Mol. Cell Biol. 35, 2218–2230 (2015). · DOI
- Richard, P. et al. PABPN1 (GCN)11 as a dominant allele in oculopharyngeal muscular dystrophy –consequences in clinical diagnosis and genetic counselling. J. Neuromuscul. Dis. 2, 175–180 (2015). · DOI · Paper page
- Gidaro, T. et al. Atrophy, fibrosis, and increased PAX7-positive cells in pharyngeal muscles of oculopharyngeal muscular dystrophy patients. J. Neuropathol. Exp. Neurol. 72, 234–243 (2013). · DOI
- Tome, F. M. & Fardeau, M. Nuclear inclusions in oculopharyngeal dystrophy. Acta Neuropathol. 49, 85–87 (1980). · DOI
- Winklhofer, K. F., Tatzelt, J. & Haass, C. The two faces of protein misfolding: gain- and loss-of-function in neurodegenerative diseases. EMBO J. 27, 336–349 (2008). · DOI · Paper page
- Conacci-Sorrell, M., Ngouenet, C. & Eisenman, R. N. Myc-nick: a cytoplasmic cleavage product of Myc that promotes alpha-tubulin acetylation and cell differentiation. Cell 142, 480–493 (2010). · DOI · Paper page
- Becher, M. W., Kotzuk, J. A., Davis, L. E. & Bear, D. G. Intranuclear inclusions in oculopharyngeal muscular dystrophy contain poly(A) binding protein 2. Ann. Neurol. 48, 812–815 (2000). · doi:10.1002/1531-8249(200011)48:5<812::aid-ana20>3.0.co;2-2
- Harish, P., Malerba, A., Dickson, G. & Bachtarzi, H. Progress on gene therapy, cell therapy, and pharmacological strategies toward the treatment of oculopharyngeal muscular dystrophy. Hum. Gene Ther. 26, 286–292 (2015). · DOI
- Trollet, C. et al. Molecular and phenotypic characterization of a mouse model of oculopharyngeal muscular dystrophy reveals severe muscular atrophy restricted to fast glycolytic fibres. Hum. Mol. Genet. 19, 2191–2207 (2010). · DOI
- Palmer, P. M., Neel, A. T., Sprouls, G. & Morrison, L. Swallow characteristics in patients with oculopharyngeal muscular dystrophy. J. Speech Lang. Hear. Res. 53, 1567–1578 (2010). · doi:10.1044/1092-4388(2010/09-0068
- Davies, J. E., Berger, Z. & Rubinsztein, D. C. Oculopharyngeal muscular dystrophy: potential therapies for an aggregate-associated disorder. Int. J. Biochem. Cell Biol. 38, 1457–1462 (2006). · DOI
- Davies, J. E. et al. Doxycycline attenuates and delays toxicity of the oculopharyngeal muscular dystrophy mutation in transgenic mice. Nat. Med. 11, 672–677 (2005). · DOI · Paper page
- Barbezier, N. et al. Antiprion drugs 6-aminophenanthridine and guanabenz reduce PABPN1 toxicity and aggregation in oculopharyngeal muscular dystrophy. EMBO Mol. Med. 3, 35–49 (2011). · DOI
- Davies, J. E., Rose, C., Sarkar, S. & Rubinsztein, D. C. Cystamine suppresses polyalanine toxicity in a mouse model of oculopharyngeal muscular dystrophy. Sci. Transl. Med. 2, 34ra40 (2010). · DOI
- Verheesen, P. et al. Prevention of oculopharyngeal muscular dystrophy-associated aggregation of nuclear polyA-binding protein with a single-domain intracellular antibody. Hum. Mol. Genet. 15, 105–111 (2006). · DOI
- Perie, S. et al. Autologous myoblast transplantation for oculopharyngeal muscular dystrophy: a Phase I/IIa clinical study. Mol. Ther. 22, 219–225 (2013). · DOI
- Chartier, A. et al. Mitochondrial dysfunction reveals the role of mRNA poly(A) tail regulation in oculopharyngeal muscular dystrophy pathogenesis. PLoS Genet. 11, e1005092 (2015). · DOI
- Kaeppel, C. et al. A largely random AAV integration profile after LPLD gene therapy. Nat. Med. 19, 889–891 (2013). · DOI · Paper page
- Borel, F., Kay, M. A. & Mueller, C. Recombinant AAV as a platform for translating the therapeutic potential of RNA interference. Mol. Ther. 22, 692–701 (2014). · DOI · Paper page
- Mendell, J. R. et al. A phase 1/2a follistatin gene therapy trial for becker muscular dystrophy. Mol. Ther. 23, 192–201 (2015). · DOI · Paper page
- Bisset, D. R. et al. Therapeutic impact of systemic AAV-mediated RNA interference in a mouse model of myotonic dystrophy. Hum. Mol. Genet. 24, 4971–4983 (2015). · DOI
- Li, C., Xiao, P., Gray, S. J., Weinberg, M. S. & Samulski, R. J. Combination therapy utilizing shRNA knockdown and an optimized resistant transgene for rescue of diseases caused by misfolded proteins. Proc. Natl Acad. Sci. USA 108, 14258–14263 (2011). · DOI · Paper page
- Stanek, L. M. et al. Silencing mutant huntingtin by adeno-associated virus-mediated RNA interference ameliorates disease manifestations in the YAC128 mouse model of Huntington's disease. Hum. Gene Ther. 25, 461–474 (2014). · DOI · Paper page
- Wang, Z. et al. Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. Nat. Biotechnol. 23, 321–328 (2005). · DOI · Paper page
- Kumar, S. R., Markusic, D. M., Biswas, M., High, K. A. & Herzog, R. W. Clinical development of gene therapy: results and lessons from recent successes. Mol. Ther. Methods Clin. Dev. 3, 16034 (2016). · DOI · Paper page
- Kharma, N. et al. Automated design of hammerhead ribozymes and validation by targeting the PABPN1 gene transcript. Nucleic Acids Res. 44, e39 (2015). · DOI
- O'Reilly, M. et al. RNA interference-mediated suppression and replacement of human rhodopsin in vivo. Am. J. Hum. Genet. 81, 127–135 (2007). · DOI · Paper page
- Millington-Ward, S. et al. Suppression and replacement gene therapy for autosomal dominant disease in a murine model of dominant retinitis pigmentosa. Mol. Ther. 19, 642–649 (2011). · DOI · Paper page
- Zhang, R. & Lin, Y. DEG 5.0, a database of essential genes in both prokaryotes and eukaryotes. Nucleic Acids Res. 37, D455–D458 (2009). · DOI · Paper page
- Apponi, L. H., Corbett, A. H. & Pavlath, G. K. Control of mRNA stability contributes to low levels of nuclear poly(A) binding protein 1 (PABPN1) in skeletal muscle. Skelet. Muscle 3, 23 (2013). · DOI · Paper page
- Davies, J. E., Sarkar, S. & Rubinsztein, D. C. Wild-type PABPN1 is anti-apoptotic and reduces toxicity of the oculopharyngeal muscular dystrophy mutation. Hum. Mol. Genet. 17, 1097–1108 (2008). · DOI
- Riaz, M. et al. PABPN1-Dependent mRNA Processing Induces Muscle Wasting. PLoS Genet. 12, e1006031 (2016). · DOI
- Corbeil-Girard, L. P. et al. PABPN1 overexpression leads to upregulation of genes encoding nuclear proteins that are sequestered in oculopharyngeal muscular dystrophy nuclear inclusions. Neurobiol. Dis. 18, 551–567 (2005). · DOI
- Tavanez, J. P., Calado, P., Braga, J., Lafarga, M. & Carmo-Fonseca, M. In vivo aggregation properties of the nuclear poly(A)-binding protein PABPN1. RNA 11, 752–762 (2005). · DOI
- Tavanez, J. P. et al. Hsp70 chaperones and type I PRMTs are sequestered at intranuclear inclusions caused by polyalanine expansions in PABPN1. PLoS ONE 4, e6418 (2009). · DOI
- Bao, Y. P., Cook, L. J., O'Donovan, D., Uyama, E. & Rubinsztein, D. C. Mammalian, yeast, bacterial, and chemical chaperones reduce aggregate formation and death in a cell model of oculopharyngeal muscular dystrophy. J. Biol. Chem. 277, 12263–12269 (2002). · DOI · Paper page
- Fan, X. et al. HnRNP A1 and A/B interaction with PABPN1 in oculopharyngeal muscular dystrophy. Can. J. Neurol. Sci. 30, 244–251 (2003). · DOI
- Calado, A. et al. Nuclear inclusions in oculopharyngeal muscular dystrophy consist of poly(A) binding protein 2 aggregates which sequester poly(A) RNA. Hum. Mol. Genet. 9, 2321–2328 (2000). · DOI · Paper page
- Bengoechea, R. et al. Nuclear speckles are involved in nuclear aggregation of PABPN1 and in the pathophysiology of oculopharyngeal muscular dystrophy. Neurobiol. Dis. 46, 118–129 (2012). · doi:10.1016/j.nbd.2011.12.052
- Klein, P. et al. Nuclear poly(A)-binding protein aggregates misplace a pre-mRNA outside of SC35 speckle causing its abnormal splicing. Nucleic Acids Res. 44, 10929–10945 (2016). · DOI · Paper page
- Abu-Baker, A. et al. Involvement of the ubiquitin-proteasome pathway and molecular chaperones in oculopharyngeal muscular dystrophy. Hum. Mol. Genet. 12, 2609–2623 (2003). · DOI
- Chartier, A., Benoit, B. & Simonelig, M. A Drosophila model of oculopharyngeal muscular dystrophy reveals intrinsic toxicity of PABPN1. EMBO J. 25, 2253–2262 (2006). · DOI · Paper page
- Bigot, A. et al. Large CTG repeats trigger p16-dependent premature senescence in myotonic dystrophy type 1 muscle precursor cells. Am. J. Pathol. 174, 1435–1442 (2009). · DOI
- Mamchaoui, K. et al. Immortalized pathological human myoblasts: towards a universal tool for the study of neuromuscular disorders. Skelet. Muscle 1, 34 (2011). · DOI · Paper page
- Li, X., Eastman, E. M., Schwartz, R. J. & Draghia-Akli, R. Synthetic muscle promoters: activities exceeding naturally occurring regulatory sequences. Nat. Biotechnol. 17, 241–245 (1999). · DOI · Paper page
- Vignaud, A. et al. Diabetes provides an unfavorable environment for muscle mass and function after muscle injury in mice. Pathobiology 74, 291–300 (2007). · DOI · Paper page
- Carvalho, B. S. & Irizarry, R. A. A framework for oligonucleotide microarray preprocessing. Bioinformatics 26, 2363–2367 (2010). · DOI · Paper page
- Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015). · DOI · Paper page
- Butler-Browne, G. S., Bugaisky, L. B., Cuenoud, S., Schwartz, K. & Whalen, R. G. Denervation of newborn rat muscle does not block the appearance of adult fast myosin heavy chain. Nature 299, 830–833 (1982). · DOI
Cited by
Hakim, C. H., Kumar, S. R. P., Pérez-López, D. O., Wasala, N. B., Zhang, D., Yue, Y., Teixeira, J., Pan, X., Zhang, K., Million, E. D., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26830-7 · Cited by 175
Mezzell, A. T., Zhang, Y., Perez, A. M., & Vest, K. E. (2026) · PLOS Genetics · doi:10.1371/journal.pgen.1011743 · Cited by 7
Metadata
- Authors
- Malerba, A., Klein, P., Bachtarzi, H., Jarmin, S. A., Cordova, G., Ferry, A., Strings, V., Espinoza, M. P., Mamchaoui, K., Blumen, S. C., St Guily, J. L., Mouly, V., Graham, M., Butler-Browne, G., Suhy, D. A., Trollet, C., & Dickson, G.
- Venue
- Nature Communications
- Published
- 2017-03-31
- Volume
- 8
- Issue
- 1
- ISSN
- 2041-1723
- Cited by
- 89
- References
- 10
- Language
- en
- Licence
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.